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Altered metabolism has long been recognized as a defining characteristic 
of tumor cells.  The increased glycolytic phenotype, an observation credited to 
Otto Warburg in 1956, is almost universal for cancer cells, making metabolic 
enzymes attractive targets for cancer therapy.  However, anti-metabolic drugs, 
thus far, have not lived up to expectations as stand-alone agents to treat this 
disease.  Unlike glycolytic enzymes that directly catabolize glucose to pyruvate, 
the family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFBs) 
control the conversion of fructose-6-phosphate to and from fructose-2,6-
bisphosphate, a key regulator of the glycolytic enzyme phosphofructokinase-1 
(PFK-1).  One isoform, PFKFB3, has been shown to be highly expressed by 
human cancer cells and a specific PFKFB3 small molecule inhibitor, (3-(3-
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pyridinyl)-1-(4-pyridinyl)-2-propen-1-one [3PO] is currently being developed for 
clinical use.  However, the effectiveness of current chemotherapeutics is limited 
by the development of drug resistance, which is especially problematic for anti-
metabolic drugs where the starvation state activates a variety of survival 
mechanisms within the cell that contribute to resistance.  One such mechanism 
used by all cells to survive nutrient-poor conditions is the activation of autophagy, 
the process of cellular self-catabolism.  Autophagic induction allows for the 
continued generation of biosynthetic intermediates that can be used for energy 
generation and critical metabolic processes while also ensuring prompt disposal 
of damaged and malfunctioning organelles before they cause cellular harm.  We 
hypothesized that the functional starvation induced by inhibition of PFKFB3 in 
tumor cells might induce autophagy as a pro-survival mechanism and that the 
combination of drugs targeting PFKFB3 with pharmacologic inhibitors of 
autophagy could increase anti-tumor effects. This hypothesis has been tested 
and our data reveal that knockdown or inhibition of PFKFB3 results in autophagic 
induction.  This induction appears to serve as a survival mechanism as 
evidenced by furthered cell death upon the addition of inhibitors of autophagy. 
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Cancer cells have altered cellular metabolism. 
 The metabolic alterations characteristic of tumor cells have now 
reached hallmark status [1].  Increased glucose uptake and utilization, first 
described by Warburg in 1956, provides biosynthetic precursors for these rapidly 
dividing cells and also may be a means by which cancer cells compensate for 
reduced ATP production [2, 3].  This counterintuitive replacement of a more 
efficient system, oxidative respiration, that generates 36 mol of ATP per mol of 
glucose, with glycolysis which only produces 2 ATP, to generate increased 
energy needed by highly proliferative tumor cells has been rationalized by the 
rapid rates at which glucose can be metabolized through glycolysis [4].   There 
are a number of theories pertaining to why tumor cells take up and utilize more 
glucose than normal cells.   Some have proposed that mitochondrial defects 
result in the preferential use of glycolysis; however, support for this view is limited 
[5-7].  Others speculate that hypoxia encountered within the tumor 
microenvironment due to outgrowing its blood supply, results in the shift to 
glycolysis [8].  Whether due to hypoxia, or to other causes, it is clear that 
changes in glucose uptake or glycolytic flux can result from changes in the 
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expression or activity of a number of key proteins involved in the glycolytic 
pathway including glucose transporter-1, hexokinase, pyruvate kinase, and a 
family of enzymes involved in the regulation of glycolysis, the PFKFBs [9-16]. 
 
PFKFB3 can regulate glycolysis by controlling levels of F2,6BP 
 Bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases 
(PFKFBs) regulate glycolytic flux by controlling the steady state concentration of 
fructose 2,6 bisphosphate (F2,6BP), a potent allosteric regulator of PFK-1[17].  
The PFKFB family consists of 4 isoforms of which PFKFB3 is of particular 
interest in tumor cells [18].  PFKFB3 mRNA and protein are increased in tumors 
when compared to normal tissue [19, 20].  This increase is mediated in part 
through repeating AUUUA elements in the 3’-UTR of its mRNA which are present 
in the mRNAs of several proto-oncogenes and have been shown to increase 
translational activity [21].  Additionally, PFKFB3 has a kinase: phosphatase ratio 
of 740:1, due to the lack of regulatory residues present on other isoforms [22].  
The result is a considerable increase in F2,6BP and subsequent upregulation of 
glycolysis following increased PFKFB3 expression [23-25].  Knockdown of 
PFKFB3 using siRNA decreases glycolysis, cell proliferation and inhibits 
anchorage-independent growth, making this enzyme a promising target for anti-
cancer therapy [26].  Despite the development of numerous anti-metabolic 
agents to treat cancer, these drugs have not seen the clinical success anticipated 
based on their pre-clinical profiles and their presumed tumor-specific activity.  




inhibitor of glucose metabolism [33] in prostate cancer patients, an autophagic 
resistance, indicated by decreased p62 expression, was observed in the majority 
of the patients treated [34].  Recently, the combination of autophagy inhibitors 
with compounds that induce metabolic stress has drawn great attention and 
chloroquine, a drug that has been shown to inhibit autophagy, is now being used 
alone and in combination with other chemotherapeutics in human cancer trials 
[35-37] 
 
Anti-metabolic targeting can mimic a low nutrient environment and lead to 
activation of autophagy  
 Cells in low nutrient environments, such as those with reduced amino 
acids or glucose, activate the cellular self-digestion process of autophagy [38-
40].  While this process occurs at a basal level within cells playing a 
complementary role with the proteasome to help clear larger and more abundant 
material, the induction of autophagy can be triggered by stressful stimuli such as 
hypoxia or nutrient deprivation.  Under these conditions, autophagy is a means 
by which cells are able to degrade cellular components to provide biosynthetic 
precursors which can be used for anabolic processes and energy production [41-
44].  Targeting cancer cell metabolism is a promising strategy for anti-tumor 
therapy due to selectivity for the more metabolically active tumor cells.  However, 
as with many other chemotherapeutic agents, cancer cells have developed 
resistance mechanisms in response to treatment with anti-metabolic drugs.  
Amongst these resistance mechanisms, the induction of autophagy may play an 
4 
 
especially critical role in conferring resistance to anti-metabolic drugs since they 
induce states that mimic low nutrient environments that can stimulate autophagy.  
For example, 2-deoxy-glucose has been shown to induce autophagy both in vitro 
and in vivo as part of a phase I clinical trial for prostate cancer [34, 45, 46].   
 
Autophagy may serve to protect cells from metabolic stress 
 Although autophagy has been implicated as either a mechanism for 
adaptive cell survival or for cell death, the process can serve either function 
depending on the stimulus, the timing, and the degree of activation.  There are 
numerous examples of the pro-survival role of autophagy in cells.  Potentially 
hazardous damaged mitochondria are routinely degraded by autophagic self-
digestion [47, 48].  Amino acids can stimulate the TCA cycle by increasing 
capacity through anaplerotic reactions that produce compounds like -
ketoglutarate.  Amino acids and fatty acids also produce acetyl-CoA which, as a 
substrate for the TCA cycle, is converted to carbon dioxide and water fueling 
cellular energetic processes [41-44].   Autophagy has also been shown to 
promote cellular survival in tumor cells treated with chemotherapeutic agents, 
e.g. etoposide, temozolomide, trastuzumab and imatinib [49-52].  Due to this 
demonstrated function of autophagy in protecting cells experiencing stress, it is 
reasonable to postulate that this process may protect cells that are confronted 






Co-targeting PFKFB3 and the autophagic pathway may result in increased 
anti-cancer effects 
 Molecular modeling has allowed for the development of novel small 
molecule inhibitors that are able to target PFKFB3 enzyme activity.  One such 
inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), has been shown to 
suppress glycolysis flux to lactate, decrease glucose uptake and attenuate the 
proliferation of human cancer cell lines in vitro [53].  Similar inhibition was also 
observed in vivo, and, although tumor growth was decreased by treatment with 
3PO, it was not completely suppressed [53].  We postulated that the metabolic 
stress caused by PFKFB3 inhibition might activate autophagy as a survival 
pathway that could confer resistance to 3PO.  Chloroquine (CQ), an anti-malarial 
agent that is relatively well tolerated and has been used in humans since the 
1940’s has been shown to inhibit autophagy and potentiate cancer cell death and 
is now being added to a number of other drugs as a part of several human 
cancer clinical trials [54-59].  We hypothesized that the combination of the 
PFKFB3 inhibitor 3PO with the autophagy inhibitor CQ might lead to a significant 
improvement in anti-cancer effect of 3PO in vitro and that this combination might 
also increase efficacy of 3PO as an anti-tumor agent in vivo which could have 






KNOCKDOWN OF 6-PHOSPHOFRUCTO-2-KINASE (PFKFB3) RESULTS IN 





 Tumor cell dependence on increased glucose uptake and glycolysis 
allows for the increased production of ATP, nucleic acids, amino acids and fatty 
acids required for proliferation [60].  Glycolytic flux is controlled through the 
irreversible, rate-limiting enzyme, PFK-1.  This enzyme is allosterically inhibited 
by ATP, which reduces flux when cellular ATP production exceeds utilization 
[61].  When energy reserves are reduced, AMP activates PFK-1.  However, 
fructose 2,6 bisphosphate (F2,6BP), is also a potent activator of PFK-1 [17].  The 
family of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatases (PFKFBs) is 
responsible for establishing the steady state levels of cellular F2,6BP. 
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The PFKFB family consists of four members, (PFKFB1-4), which act to 
regulate the concentration of F2,6BP in cells [62-64].  The PFKFB3 isoform, with 
a kinase: phosphatase ratio of 740:1, due to the absence critical residues 
required for regulating kinase and phosphatase activity [65] has been shown to 
be expressed at higher levels in tumor cells [20].   This upregulation is mediated 
in part through an AUUUA-rich region in the 3’ untranslated region of its mRNA 
which controls mRNA stability and translational activity [23, 65, 66].  The 
PFKFB3 isoform also contains a hypoxia responsive element making it a direct 
transcriptional target of HIF-1 [22, 67-69].  Finally, PFKFB3 is activated by 
mitogenic signals and is stabilized after the loss of PTEN [23, 70-75].  These 
data indicate that the PFKFB3 isoform may play a role in the increased glycolytic 
phenotype of tumor cells relative to normal cells, which has led to the interest in 
targeting PFKFB3 as an anti-cancer strategy.   Additionally, previous studies 
have shown that knockdown of PFKFB3 reduces glycolytic flux and has anti-
proliferative effects in tumors cells [26].    
The interest in PFKFB3 as an anti-tumor target has resulted in the 
development of a number of small molecule inhibitors against the enzyme [53, 
76] of which some are in the process of entering Phase I clinical trials as anti-
cancer therapeutics.   
Chemotherapies, even those with extremely promising results in vitro, have 
long been plagued by resistance when administered to cancer patients.   
Amongst the large number of resistance mechanisms, autophagy has been 
shown to be activated by a large number of chemotherapeutic agents as a pro-
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survival pathway and is now being studied as a potential target for both single 
and combination cancer therapy trials [50, 52, 77, 78]. 
Autophagy, a term first coined by Christian de Duve in 1963 is the 
evolutionarily conserved process of cellular self-catabolism [79].  Of the three 
types of autophagy, macroautophagy, microautophagy, and chaperone-mediated 
autophagy, macroautophagy is the most well-characterized and is referred to as 
autophagy in this dissertation.  Autophagy is normally active at low levels in most 
cells and functions to remove long-lived proteins and organelles.  This process 
has also been observed to protect cells by removing intracellular pathogens, 
potentially harmful damaged mitochondria and in generating metabolic 
substrates during nutrient deprivation [41-44, 80].  The process of autophagy 
involves the initial formation of a double-membraned vesicle, thought to originate 
from de novo synthesis as well as sources of cellular membrane such as the 
plasma membrane, the Golgi complex, endoplasmic reticulum or the 
mitochondrial membrane [81-87].  As maturation of this membrane continues, 
LC3-I is modified by the addition of phosphatidylethanolamine to form LC3-II 
which is incorporated into the growing membrane as a scaffolding protein [88].  
Cargo is recruited to this forming autophagosome by p62, an adapter molecule 
with ubiquitin-binding domains that recognize poly-ubiquitinated organelles, or 
proteins [89].   Ultimately, autophagosomes fuse with lysosomes where cargo is 
degraded [89].   Autophagy normally functions at basal levels in most cells can 
be induced by a variety of stressful stimuli such as hypoxia or glucose 




Regulation of autophagy is mainly controlled through inhibition by the 
mammalian target of rapamycin (mTOR) pathway.  In response to rapamycin, a 
compound isolated from soil-dwelling bacterial and originally used as an 
antimicrobial agent, mTOR activity is suppressed [91].  However, mTOR is now 
known to be regulated by other stimuli, especially signals associated with cellular 
energy status.  When nutrients are plentiful, mTOR phosphorylates and activates 
ribosomal S6 kinases resulting in increased protein translation [92, 93].  At the 
same time, mTOR blocks autophagy by inhibition of a critical component in the 
autophagic pathway, Ulk1[94].  Upon nutrient deprivation, such as that 
experienced by glucose withdrawal, the AMP:ATP ratio is altered and AMP, and 
more recently revealed, ADP,  binds to cellular energy sensor AMP-activated 
protein kinase (AMPK) causing a conformational change that favors the 
activation via phosphorylation at Thr 172 by upstream kinase LKB1 [95-98].  
Upon phosphorylation, AMPK can inhibit mTOR activity by phosphorylation of 
TSC2 which suppresses Rheb, an mTOR activator [99, 100].  AMPK can also 
directly phosphorylate ULK1 to induce autophagy [99, 101, 102].  In this way, 
nutrient deprivation can signal both the inhibition of protein translation and the 
activation of the catabolic process of autophagy [103].    
Previous studies have shown that loss of PFKFB3 expression or inhibition of 
its enzyme activity result in decreased glucose uptake, effectively starving the 
cells.  Cellular responses to metabolic stress during starvation are varied and 
depend on numerous factors including but not limited to; cell type, the 
proliferative state of the cell and the extent and time of starvation.   The induction 
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of autophagy is one response mechanism that has been shown to increase cell 
survival during times of metabolic stress by allowing for the production of 
nutrients and sustained metabolism [41-44].   
Based on the known metabolic effects of PFKFB3 targeting, we sought to 
determine the effects that knockdown of PFKFB3 would have on the activation of 
autophagy.  In the current chapter, we find that knockdown of PFKFB3 results in 
an increase in autophagy and that this increase is likely mediated through the 








Human colorectal carcinoma cells (HCT116) obtained from American 
Type Culture Collection (Manassas, VA) and were cultured with McCoy’s 5A 
medium (Gibco, Grand Island, NY) supplemented with 10% calf serum and 
50ug/mL gentamicin.  Cells were incubated at 37 C with 5% CO2. 
 
Transfection  
HCT-116 cells were plated at 100,000 cells/well of a 6-well dish in 2.5 ml 
complete medium.  24 h after seeding, cells were transfected with either control 
siRNA (Stealth Negative Control Medium GC Duplex), or PFKFB3 siRNA 
(PFKFB3HSS107860;  5’ UUCAUCAGGUAGUACACGCGGC 3’, both from 
Invitrogen, Grand Island, NY).  OptiMEM (Invitrogen, Grand Island, NY) with 1% 
Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY) was incubated at RT for 
5 minutes.  siRNA was added to the Lipofectamine mixture and incubated for 20 
minutes at room temperature.  The mixture was added to a single well of the 6-
well plate for a total volume of 3 ml and a final siRNA concentration of 10nM.  
Cells were incubated at 37 C for 48 hours before harvest.  Samples in which 
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bafilomycin A1 was used were treated with 1nM bafilomycin A1 (Sigma, St. 
Louis, MO) for 24 hours prior to harvest.  
 
Protein Extraction 
Cells were washed with PBS then lifted in 0.25% Trypsin (Gibco, Grand 
Island, NY) and pelleted by centrifugation.  Pellets were lysed in protein lysis 
buffer (Thermo, Rockford, IL) supplemented with protease and phosphatase 
inhibitors (Sigma, St. Louis, MO).  Samples were homogenized by passing 
repeatedly through a 28 ½ gauge needle and then incubated on ice for 20 
minutes before centrifugation at 2,000 g for 5 minutes at 4 C and collection of 
supernatants.  Protein concentration was determined using bicinchoninic acid 
assay (Thermo, Rockford, IL).   
 
Immunoblotting 
Equal amounts of protein were added to loading buffer (BioRad, Hercules, 
CA) containing 10ul/ml β mercaptoethanol and heated to 98 C for 5 minutes and 
then loaded onto a 4-12% gradient SDS-polyacrylamide gel (BioRad, Hercules, 
CA) and run for 60 minutes at 130 volts.  Protein was transferred to a 
nitrocellulose membrane over 1 hour at 400 mA and then blocked in 5% non-fat 
milk for 1 hour before incubation with primary antibodies.  Antibodies against 
LC3, p62, pAMPK, AMPK, p-p70S6K, p70S6K, pS6, S6 (Cell Signaling, Danvers, 
MA), PFKFB3, Tel2 (Protein Tech, Chicago, IL), β actin (Sigma, St. Louis, MO) 




p62 and β actin Ab that were incubated at room temperature for 1 hour.  
Membranes were washed for 30 minutes in Tris-Buffered Saline with Tween-20 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) before addition of 
secondary antibodies (anti-mouse or anti-rabbit, diluted 1:10,000 in TBS-T, 
(Sigma, St. Louis, MO).  ECL Western Blotting Detection Kit (Amersham/GE 
Pittsburgh, PA) was used to develop membranes.  Quantitative densitometry was 
performed using Image J (NIH). 
 
F2,6BP Assay 
 Intracellular fructose 2,6 bisphosphate (F2,6BP) levels were determined 
using a method previously described [104].  Briefly, HCT-116 cells were 
harvested 48 hours after transfection and centrifuged at 200 x g.  The pellets 
were resuspended in 50mM Tris acetate (pH 8.0) and 100 mM NaOH then 
incubated at 80 C for five minutes and then placed on ice.  Extracts were 
neutralized to pH 7.2 with 1 M acetic acid and 1 M Hepes and then incubated at 
25 C for 2 min in 50mM Tris, 2mM Mg2+, 1mM F6P, 0.15mM NAD, 10u/l PPi-
dependent PFK1, 0.45 kU/I aldolase, 5 kU/I triosephosphate isomerase, and 1.7 
kI/I glycerol-3-phosphate dehydrogenase.  0.5mM pyrophosphate was added and 
the rate of change in absorbance (OD=339 nm) per min over five minutes was 
determined.  A calibration curve using 0.1 to 1 pmol of F2,6BP (Sigma, St. Louis, 




Glucose Uptake Assay 
  HCT-116 cells were plated at 100,000 cells in each well of a 6-well dish. 
Cells were transfected with either control siRNA or siRNA directed against 
PFKFB3.  48 hours post-transfection, cells were washed with PBS and media 
was replaced with glucose-free RPMI 1640 for 30 minutes.  2-[1-14C]-deoxy-D-
glucose (Perkin Elmer, Waltham, MA) was added for 30 minutes.  Cells were 
then washed three times with ice-cold RPMI 1640 containing no glucose.  Cells 
were lysed with 0.1% SDS.  Scintillation counts (counts/min) were measured on 
a portion of lysate and normalized to protein concentration using the remainder of 
the lysate.  Data are represented as mean + SD from duplicate samples. 
 
Acridine Orange Immunofluorescence 
After 48 hours of transfection, HCT-116 cells were washed with PBS and 
then stained with 0.01mg/ml acridine orange in PBS for 15 minutes at 37 C.   
Cells were washed twice with PBS then harvested for study by microscopy or 
flow cytometry.   For immunofluorescent examination and imaging, cells were 
viewed using an EVOSfl fluorescent microscope (AMG, Grand Island, NY).  
Acridine orange was visualized using an overlay of GFP and RFP filters.  For 
flow cytometry, green (510-530nm) and red (650nm) fluorescence emission from 
10,000 cells illuminated with blue (488nm) excitation light was measured (BD 
FACSCalibur, San Jose, CA).  FlowJo software (TREE STAR Inc, San Carlos, 






HCT-116 cells were prepared for electron microscopy 48 hours post-
transfection.  Cells were washed twice with PBS and fixed in cold glutaraldehyde 
(3% in 0.1M cacodylate buffer, pH 7.4) for 30 minutes.  Samples were post fixed 
in OsO4 and 100nm sections were taken and stained with uranyl/lead citrate and 
viewed using a transmission electron microscope (Phillips CM12).  Methodology 
and identification of autophagic structures was based on established criteria and 
previous studies [105-107].   
 
ATP Determination 
 ATP levels were determined using a bioluminescence assay (Invitrogen, 
Grand Island, NY) following established protocols from suppliers.  Briefly, cells 
were lysed on cultured plates using a passive lysis buffer and snap frozen in 
liquid nitrogen then thawed at 37 C and spun at 1200 x g for 30 seconds and 
4C to clear the lysates.  Lysate was added to a prepared reaction solution 
containing reaction buffer, DTT, d-luciferin and firefly luciferase and 
luminescence was read using a luminometer (Biotek, Winooski, VT).  ATP was 
determined based on a standard curve using 1-500nM ATP and was calculated 








Knockdown of PFKFB3 results in decreased glycolytic flux 
 In order to reduce PFKFB3 levels, a siRNA directed against PFKFB3 was 
transfected into human colorectal carcinoma cells (HCT-116).  Protein 
expression, assessed by Western blotting, was inhibited by >90% at 48 hours by 
the PFKFB3-specific siRNA relative to cells transfected with the negative control 
(p value < 0.05) (Figure 1).   After confirmation of siRNA-mediated knockdown, 
the product of the enzyme, fructose 2,6 bisphosphate (F2,6BP) was measured 
using an enzyme-coupled assay.  Knockdown of PFKFB3 resulted in a 60% 
reduction in F2,6BP at 48 hours after transfection (p value < 0.05) (Figure 2).  
Blocking the production of F2,6BP leads to reduced activity of PFK-1 [23]. 
Glucose uptake was used as an indirect measure of PFK-1 activity as loss of 
PFK-1 activity results in the intracellular accumulation of glucose and its 
derivatives reducing further glucose uptake.  To measure glucose uptake 2-[1-
14C]-deoxy-D-glucose (2DG) was added to cells transfected with either a 
negative control siRNA or a siRNA directed against PFKFB3.  2DG uptake was 
reduced by more than 50% (p value < 0.05) after 48 hours in cells with reduced 









Figure 1. Treatment of cells with siRNA directed against PFKFB3 mRNA 
results in decreased steady-state levels of PFKFB3 protein. HCT-116 cells 
were transfected with either a control siRNA (ctrl) or 10nM of a siRNA directed 
against PFKFB3 (PFKFB3).  Total protein was harvested 48 hours post-
transfection and protein levels relative to β actin were determined by Western 
blotting.  Densitometry data are presented as the mean fold change + SD from 






















Figure 2. Knockdown of PFKFB3 reduces fructose 2,6 bisphosphate 
(F2,6BP) levels.   HCT-116 cells were transfected with either a control siRNA 
(ctrl) or 10nM of a siRNA directed against PFKFB3 (PFKFB3).   Fructose 2,6 
bisphosphate levels were determined using an enzyme-coupled assay. Data are 























Figure 3. 2-[1-14C]-deoxy-D-glucose uptake is reduced by PFKFB3 
knockdown. 48 hours after transfection with either control (ctrl) or PFKFB3-
specific siRNA (PFKFB3), glucose uptake was measured using 2-[1-14C]-deoxy-
D-glucose.  Data are presented as the mean counts + SD from three 


































PFKFB3 knockdown results in activation of autophagy 
 Glucose starvation is known to increase autophagy in a number of model 
systems.  Thus we sought to determine if the decrease in glucose uptake due to 
knockdown of PFKFB3 similarly increased autophagy in our model system.  Four 
measures of autophagy were used including protein markers LC3-II and p62, 
acridine orange immunofluorescence, and electron microscopy.  Knockdown of 
PFKFB3 resulted in an 8-fold increase in LC3-II protein levels relative to the 
negative control (p value < 0.05).  Addition of bafilomycin A1, a vacuolar type H+-
ATPase that inhibits lysosomal function, was used to block LC3-II degradation 
and resulted in a further increase in LC3-II, indicating autophagic flux is 
increased rather than merely a block in LC3-II degradation (Figure 4) [108, 109].   
As an additional measure of autophagy, protein levels of p62, a ubiquitin-binding 
scaffold protein that plays a role in targeting of cargo to autophagosomes, where 
it is also degraded, was measured.  Knockdown of PFKFB3 resulted in a ~90% 











Figure 4. Protein markers of autophagy, LC3-II and p62, are altered after 
knockdown of PFKFB3. 48 hours after transfection with either control (ctrl) or a 
siRNA directed against PFKFB3 (PFKFB3), LC3-II protein levels were 
determined using Western blotting.  Treatment with 1nM bafilomycin A1 (Baf A1) 
was used to determine if LC3-II levels were a result of increased autophagic flux 
or impaired degradation.  Quantitative densitometry was performed to assess 
relative protein levels.  LC3-II and p62 levels are expressed as the mean fold 










 As a second measure of autophagy, acridine orange immunofluorescence 
was used.  Acridine orange, a cell-permeable fluorescent dye, becomes 
protonated and trapped in acidic compartments such as lysosomes and, upon 
excitation (488 nM), emits a red light (650 nM).  Acridine orange 
immunofluorescence was assessed by both fluorescent microscopy and by flow 
cytometry.  HCT-116 cells transfected with PFKFB3 siRNA had a significantly 
higher emission of red light (650) when viewed by fluorescent microscopy (Figure 
5A).  Acridine orange fluorescence was quantified by flow cytometry.  PFKFB3 
knockdown resulted in a shift in FL-3 (red) fluorescence, indicating that the 
PFKFB3-siRNA transfected cells had a larger quantity of acidic compartments (p 
value <0.05), characteristic of cells with increased autophagic activity (Figure 
5B). 
 Another methodology commonly used to study autophagy is electron 
microscopy.  HCT-116 cells were transfected with PFKFB3 siRNA or a negative 
control siRNA and 48 hours post-transfection, were collected and prepared for 
electron microscopy.  Sections were studied using a transmission electron 
microscope (Phillips CM12).  An increased number of intracellular structures 
including double-membrane bound vesicles, consistent with autophagosomes 
were visualized in cells transfected with PFKFB3 siRNA [111].  Representative 










Figure 5. Acridine orange immunofluorescence is increased by PFKFB3 
knockdown.  After 48 hours of transfection with either control (ctrl) or PFKFB3-
specific siRNA, cells were stained with acridine orange and observed by 
fluorescent microscopy. Representative images were taken.  Cells were then 
collected by flow cytometry to measure the relative content of acidic 
compartments.   Data are presented as the mean percentage of cells with high 














Figure 6. Autophagic structures are visible by electron microscopy after 
knockdown of PFKFB3.  48 hours after transfection, HCT-116 were harvested 
and fixed for electron microscopy.  Microscopic examination of the cells treated 














Autophagy due to PFKFB3 knockdown may result from mTOR inhibition 
Protein collected from HCT-116 cells transfected with either a negative 
control siRNA or a PFKFB3-specific siRNA for 48 hours was used for 
immunoblotting to measure levels of proteins involved in the mTOR pathway.  
Relative to total AMPK, pAMPK was increased after 48 hours of transfection with 
PFKFB3 siRNA.  AMPK activation is known to suppress mTOR activity which can 
be measured using downstream mTOR effectors p70 S6 kinase (p70S6K) and 
ribosomal protein S6 (S6).  The phosphorylated forms of both p70S6K and S6 
were decreased by PFKFB3 knockdown, relative to their total expression level 
(Figure 7) indicating suppression of the mTOR pathway.  mTOR inhibition 
resulting from AMPK activation can occur when the intracellular ATP is reduced 
relative to AMP [112].  ATP levels after PFKFB3 knockdown were determined 
using a bioluminescence assay.  48 hours post-transfection, PFKFB3 knockdown 
resulted in a ~30% decrease in ATP (p value <0.05) (Figure 8).  Taken together, 
these data indicate that suppression of glucose uptake may result in decreased 
ATP, increased AMPK activation, mTOR pathway inhibition and resultant 








Figure 7. Protein markers downstream of mTOR are decreased by PFKFB3 
knockdown.  After 48 hours of transfection with either a control or a PFKFB3-
specific siRNA, protein expression of both phosphorylated and total levels of 
downstream mTOR targets, p70S6K and ribosomal protein S6 (S6) were 
measured using Western blotting.  Activating phosphorylation of a well-studied 
upstream inhibitor of mTOR activity, AMPK, was also measured.  Quantitative 
densitometry is reported as phosphorylated relative to total protein for AMPK, 
p70S6K and S6 and relative to β actin for LC3.  All are relative to control.  Data 


















Figure 8. PFKFB3 knockdown reduces ATP levels.  HCT-116 cells were 
transfected with either a control or a PFKFB3-specific siRNA.  48 hours after 
transfection cells were harvested for ATP determination.  ATP was measured 
using a bioluminescence assay and data are presented as the mean + SD of 




















































 Members of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
(PFKFB) family have been shown to be highly expressed in neoplastic relative to 
normal tissue [19, 20].  This increase in expression occurs concurrently with 
increased glucose uptake and utilization by tumors.  For these reasons, the 
family of PFKFBs has become an attractive target for anti-cancer drug 
development.  The PFKFB3 isoform is of particular interest in this pursuit due to 
the considerable imbalance of this enzyme’s kinase to phosphatase activity.  
Increased activity of PFKFB3 results in the production of a large amount of 
F2,6BP, resulting in PFK-1 activation and increased glycolytic flux [18, 20, 26].    
Inhibition of PFKFB3 has been shown to reduce glucose uptake in vitro and in 
vivo.  Although the precise mechanism for decreased glucose uptake is not well 
defined, suppression of PFK-1 activity caused by decreased F2,6BP is expected 
to increase F6P which is in equilibrium with G6P, a potent inhibitor of hexokinase 
and, thus, of glucose uptake [113].  However, tumor cells are quite 
heterogeneous as a result of ongoing genetic alteration such that even cells 
within a single tumor can have distinctly different responses to a stimulus.  For 
this reason it is important to validate each model system used when studying the 
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effects of genetic manipulation of a target.   To evaluate the effect of PFKFB3 
knockdown, a siRNA approach was used in a transformed cell line derived from a 
human colon adenocarcinoma (HCT-116).  Knockdown of PFKFB3 in this cell 
line resulted in a substantial reduction in PFKFB3 protein expression.  At the 
same time there was also a decrease in glucose uptake and in fructose 2,6 
bisphosphate production as would be expected with reduced PFKFB3 
expression.    
 The metabolic stress caused by reduced glucose availability results in a 
number of cellular defense mechanisms critical to survive transitory periods of 
starvation.  These include the suppression of energy-requiring processes by 
reducing the expression of biosynthetic genes, inhibiting the activity of 
translational machinery and halting the cell cycle [114-116].  At the same time, 
catabolic processes, such as autophagy, are used to recycle intracellular 
components in order to provide metabolic substrates which can then be used to 
generate energy as well as to remove potentially harmful intracellular material 
such as damaged mitochondria [41, 44, 117-119].  To determine if the reduced 
glucose uptake due to knockdown of PFKFB3 caused cells to activate this 
catabolic process, autophagy markers were assessed.   
Knockdown of PFKFB3 in this model system resulted in changes in 
protein markers involved in the autophagic process.  There was an increase in 
the lipidated form of the autophagosomal membrane protein LC3 and a decrease 
in protein levels of cargo protein p62 in cells transfected with PFKFB3 siRNA.  
Microtubule-associate protein 1 light chain 3-II (LC3-II) is a component of the 
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autophagosomal membrane.  LC3 is cleaved to LC3-I which liberates a C-
terminal glycine that allows the conjugation to phosphatidylethanolamine (PE) 
whereupon it can target the autophagosomal membrane.  Although 
counterintuitive, the heavier LC3-II migrates faster than LC3-I due to its 
hydrophobicity, and is seen as the lower band in Western blotting (Figure 4).  [88, 
120].  Increased LC3-II can indicate either increased autophagic synthesis or 
reduced autophagic degradation.  The addition of bafilomycin A1, an inhibitor of 
the vacuolar type H+-ATPase, allows for the determination of autophagic flux by 
inhibiting lysosomal acidification and blocking degradation of LC3-II [88, 121, 
122].  The further increase in LC3-II protein observed in the presence of 
bafilomycin A1 after knockdown of PFKFB3 indicates that knockdown is inducing 
autophagy rather than merely causing a block in LC3-II degradation.  PFKFB3 
knockdown also resulted in decreased p62 protein levels.  p62 is an autophagy 
cargo receptor protein that contains an LC3-interacting region that targets it and 
its cargo to the autophagosome.  In autophagy competent cells, this cargo 
protein is degraded along with autophagosomal contents resulting in decreased 
total levels [123].   
Additionally, knockdown of PFKFB3 resulted in cells with a higher volume 
of acidic compartments as measured using acridine orange staining, consistent 
with increased autophagy.  When visualized by electron microscopy, PFKFB3 
knockdown also resulted in the appearance of autophagosomal structures.    





Based on these observations, it appears that cells respond to PFKFB3 
knockdown by increasing autophagic processing.  Protein expression suggests 
that this induction is via the energy sensing AMPK/mTOR pathway based on an 
increased amount of phosphorylated AMPK and a decrease in the 
phosphorylated forms of downstream mTOR effectors p70 S6 kinase and 
ribosomal protein S6.  However, because gene silencing is not currently a widely 
used cancer therapy technique, the significance of these studies in the setting of 
human disease cannot be determined using knockdown methodologies alone.  
To increase its relevance most targeting is aimed at the identification of 
compounds with anti-tumor efficacy.  The interest in PFKFB3 as an anti-cancer 
target has resulted in the identification and validation of a number of compounds 
that inhibit enzyme function.  In order to determine if these observations made 
using genetic knockdown might result in meaningful advances in tumor therapy, 
further studies were conducted using a PFKFB3 small molecule inhibitor that had 







INHIBITION OF PFKFB3 USING 3-(3-PYRIDINYL)-1-(4-PYRIDINYL) 







The interest in PFKFB3 as a drug target for cancer treatment has now 
resulted in the identification of small molecule inhibitors of enzyme activity [53, 
76].  Molecular modeling allowed for the computational screening of a large 
number compounds with the potential to bind the fructose-6-phosphate binding 
pocket of PFKFB3.  Further validation of selected compounds resulted in the 
identification of a compound with dose-dependent inhibition of PFKFB3, termed 
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Figure 9).  This compound 
was shown to suppress glucose uptake and F2,6BP production and, importantly, 
seemed to be cancer-specific due to the selective suppression of growth of 
transformed cells relative to untransformed cells [53].  Using this inhibitor, we 




Since a reduction in PFKFB3 activity results in decreased cellular glucose 
uptake, and glucose starvation is an established stimulus for increased 
autophagic flux, it was hypothesized that starvation due to PFKFB3 inhibition 
would increase autophagic flux.  In the following results section, treatment of 
transformed cells with 3PO is shown to result in increased autophagy.  
Interestingly, the mechanism by which autophagy is induced following drug 
treatment does not appear to be the same as that observed using siRNA 
mediated knockdown.  Although PFKFB3 inhibition using 3PO results in 
decreased ATP, this change does not occur until long after the effects on 
metabolism.  The very early effects of 3PO on glucose uptake and F2,6BP 
relative to that with siRNA-mediated knockdown pointed to another source for 












Figure 9. 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was designed 
to inhibit PFKFB3 activity.  Computational modeling led to the identification of a 
small molecule inhibitor of PFKFB3 termed -(3-pyridinyl)-1-(4-pyridinyl)-2-propen-
1-one (3PO) (Figure 9A).  This compound can be seen within the PFKFB3 




















Cells were cultured as described in Chapter II. 
 
Drug Treatment 
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Advanced Cancer 
Therapeutics).  Samples in which bafilomycin A1 was used were treated with 
1nM bafilomycin A1 (Sigma, St. Louis, MO) 24 hours prior to harvest. 
 
Protein Extraction and Immunoblotting 
Protein extraction and Western blotting were performed as described in 
Chapter II.  
 
F2,6BP Assay 
 Intracellular fructose 2,6 bisphosphate (F2,6BP) levels were measured 




Glucose Uptake Assay 
  Glucose uptake after two or eight hours of treatment was measured using 
2-[1-14C]-deoxy-D-glucose as described in Chapter II. 
 
 
Acridine Orange Immunofluorescence 




HCT-116 cells were prepared for electron microscopy 24 hours after drug 
treatment as described in Chapter II.  
 
ATP Determination 
 ATP levels were determined after 6, 12 or 24 hours of treatment as 
described in Chapter II.   
 
Glutathione Measurement 
GSH-Glo Glutathione Assay (Promega) was used to measure total glutathione 
levels following manufacturer’s protocol.  Briefly, cells were lifted and washed in 
PBS.  10,000 cells from each sample were added each well of an opaque 96-well 
plate.  Cells were lysed with passive lysis buffer containing luciferin-NT (+ NEM 
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for the measurement of GSSG).  Luciferin generation reagent containing DTT, 
glutathione-S-transferase and glutathione reaction buffer was added and the 
plate was incubated at room temperature for 30 minutes.  Luciferin detection 
reagent was added and plate was read using a luminescence reader after 15 
minute incubation at room temperature.  Glutathione was calculated based on a 
standard curve generated using 0.25 to 16 M GSH. 
 
Reactive Oxygen Species Flow Cytometry 
1nM 2’,7’ –dichlorofluorescein diacetate (DCFDA) (Molecular Probes) was 
diluted in 1X PBS containing magnesium and calcium (Gibco) and added to 
washed cells and incubated at 37C for 30 minutes before being analyzed by a 
flow cytometry (BD FACSCalibur, San Jose, CA).  Data was analyzed using 
FlowJo software (TREE STAR Inc, San Carlos, CA).  Results were calculated as 
average of triplicate samples + SD. 
 
Flow Cytometry for Cell Death 
Cells were stained with annexin-V labeled with FITC and propidium iodide 
following manufacturer’s protocol (BD Biosciences).  Briefly, cells were lifted and 
pelleted by centrifugation at 2,500 rpm for 5 minutes.  Cell pellets were washed 
with 1X PBS and 100,000 cells were pelleted by centrifugation at 2,500 rpm for 5 
minutes.   Pellets were resuspended in 1X Binding Buffer and Annexin-V/FITC 
and/or Propidium Iodide was added and cells were incubated in the dark at room 




and 10,000 events were counted for each sample using the appropriate filters for 
FITC and PI detection (BD FACSCalibur, San Jose, CA).  Data was analyzed 
using FlowJo software (TREE STAR Inc, San Carlos, CA).  Results were 







Small molecule inhibition of PFKFB3 decreases glucose uptake 
 A small molecule designed to target the fructose-6-phosphate binding site 
of the PFKFB3 enzyme has previously been shown to suppress glycolysis, inhibit 
recombinant PFKFB3 activity, and decrease glucose uptake and fructose 
2,6,bisphosphate (Figure 9).  This inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-
propen-1-one (3PO), has also been used as an anti-tumor agent in vivo.  To 
validate this small molecule in our model system HCT-116 cells were treated and 
fructose 2,6 bisphosphate levels and glucose uptake were measured.  HCT-116 
cells were treated with either vehicle alone or 10 M 3PO.  Fructose 2,6 
bisphosphate was measured using an enzyme-coupled reaction and a sharp 
~50% drop in fructose 2,6 bisphosphate was noted only 2 hours after drug 
treatment (Figure 10).  3PO-treated cells were also assessed for glucose uptake 
using 2-[1-14C]-deoxy-D-glucose.  Relative to vehicle treated cells, ~35% reduced 
glucose uptake was observed in 3PO treated cells as early as two hours after 









Figure 10. Small molecule inhibition of PFKFB3 reduces fructose 
2,6,bisphosphate (F2,6BP) levels.  To determine the activity of 3PO in the 
current model system, HCT-116 cells were treated with 10 M 3PO and cells 
were harvested to measure fructose 2,6 bisphosphate using an enzyme coupled 
assay.  Data are presented as the mean pmol/mg protein + SD from three 
























Figure 11. A small molecule inhibitor of PFKFB3, 3PO, reduces 2-[1-14C]-
deoxy-D-glucose uptake.  2-[1-14C]-deoxy-D-glucose uptake was measured in 
HCT-116 cells treated with either vehicle or 10 M 3PO.  Data are presented as 












+ 3PO (10 M) 
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Inhibition of PFKFB3 induces autophagy 
Multiple markers of autophagy were measured following small molecule 
inhibition of PFKFB3.  Treatment of HCT-116 cells with 7.5, 10, or 15 M 3PO for 
24 hours led to the increased expression of protein marker LC3-II in a dose 
dependent manner.  Like PFKFB3 knockdown, the LC3-II induction by 3PO is 
likely due to increased synthesis rather than a blockade of protein degradation as 
indicated by the further increase in LC3-II upon addition of bafilomycin A1 (Figure 
12).  3PO also resulted in a decreased amount of p62 (Figure 12).   
 Treatment with 7.5, 10, or 15 M 3PO for 24 hours increased acridine 
orange immunofluorescence which was visualized by fluorescent microscopy 
(Figure 13) and quantified using flow cytometry (Figure 13).  This induction of 
fluorescence was also noted to occur in a dose dependent manner. 
 HCT-116 cells treated with 10 M 3PO were examined by electron 
microscopy.  After 24 hours of treatment, cells exposed to 3PO were noted to 










Figure 12. Markers of autophagy, LC3-II and p62, are altered by 3PO.  HCT-
116 cells were treated with either vehicle, or 7.5, 10, or 15 M 3PO for 24 hours.  
Addition of bafilomycin A1 (Baf A1) was used to determine if the changes in LC3-
II were the result of increased synthesis or impaired degradation.  Quantitative 
densitometry was conducted and protein expression was determined relative to β 
actin and to control. (LC3-II quantitation is relative to control + bafilomycin due to 
the absence of a visible band in the control sample).  Data are presented as the 
























Figure 13:  3PO increases acridine orange immunofluorescence.     HCT-
116 cells were treated with either vehicle or 7.5, 10, or 15 M 3PO.  24 hours 
after treatment, cells were stained with 1ug/ml acridine orange for 15 minutes 
and then viewed using a fluorescent microscope.  Representative images were 
captured (Figure 12A).  Cells were then harvested for flow cytometry.  Gating 
was used to quantitate the number of cells with a high AO fluorescence and 
expressed relative to vehicle (Figure 12B, C).  Data are presented as the mean 

















Figure 14:  Inhibition of PFKFB3 results in autophagic structures visualized 
by electron microscopy. HCT-116 cells treated with 10 M 3PO were 
harvested after 24 hours and prepared for electron microscopy.  Representative 











mTOR inhibition following 3PO treatment does not correlate with AMPK 
Protein lysates prepared from HCT-116 cells treated with 3PO (10 M) 
were examined for protein expression and phosphorylation of downstream 
mTOR effectors p70S6K and S6.  The levels of phosphorylated p70S6K and S6 
were decreased after treatment with 3PO, indicating mTOR inhibition similar to 
that seen with knockdown of PFKFB3.  However, unlike the knockdown, 3PO did 
not result in the activation of AMPK (Figure 15).   The lack of AMPK activation 
was appropriate, however, because ATP was not found to decrease until 24 










Figure 15:  3PO treatment results in decreased expression of downstream 
mTOR effectors.  HCT-116 cells were treated with 10 M 3PO and harvested at 
specified times for protein lysates.  Immunoblotting was performed using 
antibodies to detect pAMPK, AMPK, p-p70S6K, p70S6K, pS6, S6, β actin and 
LC3.  Quantitative densitometry was used to determine protein expression and is 
expressed as phosphorylated relative to total levels for AMPK, p70S6K and S6 
and relative to β actin for LC3-II.  All values are expressed as fold change relative 
to control and are presented as the mean fold change + SD of three experiments. 


















Figure  16: ATP levels are decreased by treatment with 3PO.  Cells treated 
with 10 M 3PO were harvested at specified times and intracellular ATP was 
measured using a bioluminescence assay.  ATP levels are expressed as mean 











PFKFB3 inhibition with 3PO increases oxidative stress 
 Glucose starvation is known to induce oxidative stress [124, 125].  After 
determining that 3PO reduced fructose 2,6 bisphosphate and glucose uptake 
very soon after treatment, we sought to determine the effect of 3PO on oxidative 
stress, focusing on glutathione levels and reactive oxygen species.  HCT-116 
cells were treated with 10 M 3PO and harvested for glutathione measurement 
using a luminescence-based assay.  After 2 hours of treatment, 3PO-treated 
cells had a ~40% decrease in glutathione relative to control (p value < 0.05) 
(Figure 17).    To determine if this prompt change in glutathione had an impact on 
reactive oxygen species, a flow cytometry approach was employed.   
Fluorescence of 2’,7’ –dichlorofluorescein diacetate (DCFDA), a dye that is used 
to measure hydroxyl, peroxyl and other reactive oxygen species was determined 
by flow cytometry.  Reactive oxygen species were increased by more than 50% 













Figure 17:  3PO treatment causes a reduction in glutathione.  Glutathione 
was measured using a luminescence-based assay in HCT-116 cells treated with 
either vehicle or 10 M 3PO.   Glutathione was calculated as g GSH/ g protein 
relative to vehicle treated cells and is expressed as the mean + SD from three 






















Figure 18:  Reactive oxygen species are increased by treatment with 3PO.  
HCT-116 cells treated with either vehicle or 10 M 3PO were harvested at 
specified time points and loaded with 2’,7’-dichlorofluorescein diacetate (DCFDA) 
for determination of reactive oxygen species by flow cytometry.  Average 
geometric mean of fluorescence intensity calculated as the relative mean + SD 












Activation of autophagy due to PFKFB3 inhibition is rescued with NAC 
 The correlation between oxidative stress and autophagy was further 
examined using the anti-oxidant N-acetylcysteine, which can act as a precursor 
to the antioxidant glutathione.  The drop in glutathione after 10 M 3PO treatment 
was partially rescued by the addition of 1mM N-acetylcysteine (Figure 19).  N-
acetylcysteine also partially blocked the increase in reactive oxygen species 
induced by 3PO, as determined by flow cytometric measurement of DCFDA 
fluorescence (Figure 20).  This rescue of glutathione and reduction in ROS 
following 3PO treatment in combination with NAC also blocked the induction of 
autophagy as measured by loss of LC3-II (Figure 21) and a reduction in acridine 
orange immunofluorescence (Figure 22). 
 N-acetylcysteine also rescued HCT-116 cells from cell death due to 
treatment with 3PO.   Flow cytometric analysis of cell death using  Annexin V and 
Propidium Iodide staining revealed a marked reduction in both early and late 












Figure 19: N-acetylcysteine prevents 3PO induced reduction in glutathione 
levels. HCT-116 cells were treated with either vehicle or 10 M 3PO + 1mM 
NAC and harvested after eight hours of treatment for measurement of glutathione 
levels using a luminescence-based assay.  Glutathione values were calculated 
as g GSH/ g protein relative to control + NAC and are expressed as the mean 























































Figure 20: Reactive oxygen species production by 3PO is rescued by N-
acetylcysteine.  2’,7’-dichlorofluorescein diacetate (DCFDA) fluorescence was 
measured using flow cytometry in HCT-116 cells treated for eight hours with 
either vehicle or 10M 3PO + 1mM NAC.  Average geometric mean was 
calculated relative to control and is expressed as the relative mean + SD from 
















Figure 21: LC3-II induction by 3PO is blocked by N-acetylcysteine.  After 
eight hours of treatment with either vehicle or 10 M 3PO + 1mM NAC, cell 
lysates were prepared and LC3-II levels were determined using immunoblotting.  
Quantitative densitometry was performed and expressed as the fold change 


















Figure 22: 3PO-induced acridine orange immunofluorescence is blocked by 
N-acetylcysteine.  After 24 hours of treatment with either vehicle or 10 M 3PO 
+ NAC, HCT-116 cells were stained with 1ug/ml acridine orange for 15 minutes.  
Fluorescence microscopy was used to capture representative images (Figure 
22B).  Cells were then harvested and acridine orange fluorescence was 
determined using flow cytometry.  Fluorescence intensity was calculated as 

















Figure 23: N-acetylcysteine rescues cells from death after treatment with 
3PO.  Cell death was measured in HCT-116 cells treated with either vehicle or 10 
M 3PO + 1mM NAC.  Annexin-V and PI stained cells were collected using flow 
cytometry (Figure 23A).  The percentage of cells with either annexin-V only 
staining or annexin-V/PI staining were determined and expressed as a 
percentage relative to control + SD from three experiments (Figure 23B, C). (p 
















The observation that PFKFB3 is overexpressed in neoplastic relative to 
normal tissues prompted the concept that targeting PFKFB3 expression may be 
a useful anti-cancer approach.  Genetic manipulation is commonly used as a 
starting point to understand the importance of specific genes and proteins.  
Knockdown of PFKFB3 using gene silencing resulted in enzyme inhibition.  
However, as presented in Chapter II of this dissertation, knockdown of PFKFB3 
also led to increased autophagic flux, presumably as a resistance mechanism to 
the knockdown.  To expand these findings in a way that is more relevant and 
applicable to treating human disease, a drug-based approach was employed. 
A drug that had previously been shown to inhibit PFKFB3, 3PO, was used 
to treat HCT-116 cells.  Similar to PFKFB3 knockdown, PFKFB3 inhibition using 
3PO reduced glucose uptake as well as reduced the levels of F2,6BP in this 
model system.  Corresponding to the changes seen after PFKFB3 knockdown, 
inhibition with 3PO also resulted in increased autophagic flux, as measured using 
protein markers, acridine orange staining and electron microscopy.  
Knockdown of PFKFB3 resulted in decreased ATP levels and an increase 
in AMPK activation as measured by phosphorylation.  Since knockdown usually 
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results in a gradual change in protein expression and drug treatment has a more 
immediate effect it was not surprising that 3PO did not seem to activate AMPK as 
was seen with PFKFB3 knockdown.  In fact, ATP levels did not even begin to 
decrease after 3PO treatment until at least 24 hours.  Still, phosphorylated 
protein markers downstream of mTOR, phospho-p70S6K and phospho-
ribosomal protein S6 were found to be decreased even in the absence of AMPK 
activation.  This indicated that for the acute response, an alternative mechanism 
was involved in mTOR suppression and autophagy activation.  Autophagy 
induction, even that induced by metabolic stress, has been shown to occur 
independently of ATP and AMPK as the result of other stimuli such as 
endoplasmic reticulum (ER) stress or through SIRT1/FOX01/3 [126-128].  
Additionally, starvation can result in decreased glutathione and the accumulation 
of reactive oxygen species [125, 129], and this oxidative stress is another 
stimulus for autophagic induction which can serve as a survival mechanism, 
mitigating damage by degrading oxidized proteins and by degrading damaged 
mitochondria [36-38, 130-138]  There is abundant evidence that oxidative stress-
induced autophagy occurs through inhibition of the mTOR pathway [125, 131, 
139-142]. 
Oxidative stress is recognized as a potent activator of autophagy and can 
also be increased under stressful stimuli such as glucose starvation [125, 141, 
143].  Nutrient deprivation can lead to oxidative stress due to the accumulation of 
reactive oxygen species (ROS).  ROS, reactive molecules that contain oxygen, 




levels in all cells, serving as signaling molecules [144] and playing a role in 
immune function [145, 146].  However, when improperly regulated, ROS can 
cause damage to intracellular macromolecules and organelles [147] .  The main 
defense against ROS is the action of anti-oxidants, including catalases, 
superoxide dismutases, and glutathione.  Glutathione (GSH), a tripeptide formed 
by glycine, cysteine and glutamate, is the most abundant intracellular non-protein 
thiol and plays a critical role in limiting oxidative damage by scavenging ROS.  
Glutamylcysteine synthetase initiates the formation of GSH by catalyzing an 
amide linkage between glutamate and cysteine.  Glycine is then added by GSH 
synthetase to complete the formation of GSH.  Donation of electrons to ROS 
leads to the formation of an oxidized thiol radical (GS) which can then form a 
disulfide bond with another thiol radical to form GSSG.  Accumulation of GSSG 
can be toxic and normally accounts for about 1% of the total cellular glutathione 
[148]  GSSG can be converted back to GSH by glutathione reductase, which 
requires reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an 
electron donor.  GSSG can also be transported across the plasma membrane as 
a way to prevent accumulation [149].  GSH may also have ROS-independent 
protective effects on cell function, some of which may be due to its function in 
glutathionylation [150-152].  Data presented here indicate that 3PO treatment 
results in a rapid decline in GSH as well as ROS accumulation. 
Autophagic induction by 3PO seems to depend on oxidative stress, as 
supported by rescue using N-acetylcysteine.  N-acetylcysteine, a compound with 
a reactive thiol group capable of reducing free radicals and a precursor to 
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glutathione, rescues not only the oxidative stress caused by 3PO, seen as a 
return in GSH and ROS levels towards that seen with vehicle treatment, but also 
prevents autophagic induction.  At this time, the mechanism by which 3PO leads 
to an increase in oxidative stress, whether by increasing ROS which results in 
depletion of GSH, or by first causing depletion in the GSH pool resulting in the 
accumulation in ROS, is unclear.  However, the induction of autophagy by the 
PFKFB3 inhibitor 3PO does appear to depend on oxidative stress and there is 
evidence that it may be through inhibition of mTOR, a pathway noted to be 
involved in autophagic induction by oxidative stress [153, 154].  While 3PO has 
mostly cytostatic effects at low doses, cytotoxicity is observed at high doses or 
after long periods of exposure.  This cytotoxicity is almost completely abrogated 
upon the addition of NAC suggesting that inducing oxidative stress is a 
mechanism by with 3PO can result in cell death.  However, the larger percentage 
of cells that survive treatment with 3PO suggests that these cells could be 
responding to the oxidative stress in order to prevent cell death.  Autophagy is a 
well-known defense against oxidative stress [138, 155].  Thus, inhibiting 
autophagy in the setting of 3PO treatment could shift this resistant population 
towards cell death.     
Although through two distinct biochemical mechanisms, autophagy was 
induced by both the knockdown of PFKFB3 using siRNA and by enzyme 
inhibition using 3PO.  The interest in PFKFB3 inhibitors as a new cancer 
treatment option means that recognition of potential drug resistance mechanisms 




Autophagy is now a widely recognized process induced by stimuli such as 
nutrient deprivation or chemotherapeutic drugs.  However, there is some 
disagreement as to the function of autophagy as a tumor suppressive versus as 
a tumor survival mechanism.  In support of a tumor suppressive mechanism, the 
mammalian orthologue of yeast Atg6, Beclin1, is deleted in large number of 
human cancers including breast, ovarian and prostate cancers [156].  In this 
regard, autophagy is theorized to reduce genomic instability.  Loss of this 
process, by deletion of Beclin1, results in tumorigenesis due to increased 
genomic instability.  Additionally, autophagy has been seen to prevent necrotic 
inflammation which prevents the release of tumor promoting cytokines [90] and 
the persistent activation of autophagy can eventually lead to death via a 
caspase-independent mechanism [157].  The oncogenic regulation of autophagy 
is also not entirely clear.  Some tumor suppressors (e.g. PTEN)  
activate autophagy, and some oncogenes can inhibit autophagy (Akt, Ras, ERK) 
while others, such as p53, have been shown to both activate and inhibit 
depending on the context [158-162].  Still, despite these indications that 
autophagy may suppress tumor initiation or growth, there is more evidence that 
autophagy is actually a tumor survival mechanism.  In order to metastasize, 
tumor cells must overcome matrix detachment-induced cell death, anoikis.  
Autophagy has been shown to be protective against cell death during this 
process which may function in facilitating metastatic spread [163].  Autophagy 
can also serve to promote survival of dormant tumor cells which could have 
major implications for adjuvant therapies aimed at preventing recurrence. [164, 
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165].  This role of autophagy in dormancy is the result of reduced proliferation, 
the same function that is also touted as a tumor suppressive function.  However, 
the function to reduce proliferation until adequate nutrients or a more conducive 
environment are encountered is surely one that can be viewed as tumorigenic 
rather than suppressive.  Additionally, there is now considerable evidence that 
the combination of inhibitors of autophagy with drugs that induce autophagy in 
cancer cells can increase tumor cell death [77, 158, 166-168] 
The most currently accepted model of autophagy is that of a process with 
a dual nature, depending on tumor type and stage.  Autophagy may suppress 
tumor initiation via reduced genomic instability and prevention of chronic 
inflammation and necrosis, while later serving as a cell survival mechanism by 
allowing stress tolerance through increased production of metabolic precursors, 
mitigating excessive damage that can be caused by damaged mitochondria, and 
facilitating metastasis by protecting from anoikis-induced cell death.  
To determine if the autophagy induced by knockdown or inhibition of 
PFKFB3 could be exploited to increase efficacy as an anti-tumor agent, the next 
step was to evaluate how tumor cells reacted to the combination of PFKFB3 






INHIBITION OF PFKFB3 HAS ADDITIVE ANTI-TUMOR 







While there was an indication of cytotoxic activity of 3PO in transformed 
cells, this toxicity occurred at concentrations that also had toxic effects on 
untransformed cells.   At lower concentrations, when the drug was found to 
influence transformed cells more than normal cells, the effect was more 
cytostatic [53].  In vivo tumor experiments using 3PO resulted in a significant 
reduction in tumor growth relative to vehicle treated animals.  However, tumors in 
animals treated with 3PO, while smaller than the controls, continued to grow 
through drug treatment.  Like most drugs currently used to treat human cancers, 
3PO seemed to have restricted efficacy as a single drug option, making rational 
drug combination an important step to ensure maximal efficacy when used to 
treat human cancer patients.    
The majority of cancers not amenable to surgical removal are treated with 
combinations of chemotherapeutic drugs.  It is well known that neoplastic cells 
are capable of evading and resisting treatment making the recognition of 
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resistance mechanisms imperative to the identification of successful 
combinations of drugs to counter such defenses.  There are numerous 
mechanisms employed by tumor cells to avoid death caused by 
chemotherapeutic agents.  In some tumors, cells have membrane protein pumps 
that prevent drug from accumulating inside [149, 169].  Other mechanisms 
involve changes that reduce the sensitivity to drug-induced apoptosis, allowing 
for survival even in the presence of pro-apoptotic signals [170].  Another way that 
tumor cells resist destruction is through the activation of autophagy, a ubiquitous 
intracellular catabolic processing pathway [41-44].   An increase in autophagic 
processing results in the degradation of intracellular proteins and organelles for 
the production of biosynthetic precursors can be used to fuel the continued 
production of ATP and lead to cell survival under adverse conditions.  Autophagy 
is now recognized as a major resistance mechanism of tumors to a large number 
of drug therapies [50-52, 55, 57, 78].  The cause for increased autophagic flux is 
not always identified but, nonetheless, can be taken advantage of by the addition 
of autophagy inhibitors to therapy regimens.    
The increased detection of autophagy due to drug treatment in cancer has 
resulted in great interest in the use of autophagy inhibitors in cancer therapy.  
While there are now a number of drugs known to inhibit autophagy, the drug that 
is currently the most widely used for this purpose is chloroquine, a drug that was 
originally developed as an anti-malarial agent.   
Chloroquine is a 4-aminoquinoline drug that has been used to treat 




be treated using the bark of cinchona trees led to the isolation of quinine.  The 
molecular structure of quinine was determined and later, a derivative with potent 
anti-malarial activity called Resochin, N’-(7-chloroquinolin-4-yl)-N,N-diethyl-
pentane-1,4-diamine, and later renamed chloroquine, was produced [171, 172].  
Chloroquine in an unprotonated form can diffuse across membrane bilayers.  
However, once protonated in the lysosome, chloroquine is no longer able to exit 
and accumulates resulting in the inhibition of lysosomal enzymes such as 
phospholipase A2, lysophospholipid acylhydrolase [173, 174].   This inhibition 
blocks the final step of autophagy, degradation on autophagosomal contents by 
lysosomal enzymes.   Chloroquine was later shown to be effective in treating 
other diseases such as rheumatoid arthritis and HIV [175-177].   The observation 
of a reduced incidence of Burkitt’s lymphoma in malaria patients treated with 
chloroquine was made in 1989 [178].  More recently, chloroquine has been 
shown to reduce autophagy in vivo and to potentiate the anti-cancer effects of 
some cancer therapies [55, 167, 179, 180].   The relatively mild safety profile and 
widely accepted use of chloroquine makes this compound attractive for use in a 
combination drug trial for cancer.  As such, chloroquine is currently being used in 
combination with a number of other agents as part of clinical trials, including 
carmustine, paclitacel, gefitinib, and temozolomide among others reviewed in 
[181]. 
To determine the effect of autophagy inhibition in combination with 
PFKFB3 inhibition in transformed cells, HCT-116 cells were treated with 
combinations of PFKFB3 inhibitors and autophagy inhibitors and cell death was 
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measured.  The addition of autophagy inhibitors to PFKFB3 inhibitors resulted in 
more cell death than either inhibitor alone.  While these results were 
encouraging, in vitro assays do not always accurately predict the effects of 
certain treatments when used in vivo.  This can be due to a number of factors 
including the tumor microenvironment, such as access to blood supply and 
nutrients, or to the heterogeneous nature of tumors.  Additionally, systemic 
effects such as drug metabolism or activation/inactivation and unexpected 
toxicities are impossible to predict using an in vitro modeling system.  As 
predicted, tumors from animals treated with the combination of 3PO and 
chloroquine grew significantly slower relative to animals treated with either drug 
alone.  While a significant amount of work needs to be done before these results 
can translate into an effective treatment option for human cancer patients, data 
here support the increased efficacy of PFKFB3 inhibitors when combined with 
inhibitors of autophagy. 
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Human colorectal carcinoma cells (HCT116) were cultured as described in 
Chapter II.  Lewis lung carcinoma cells (LLC) obtained from American Type 
Culture Collection (Manassas, VA) were cultured in Dulbecco’s Modified Eagle 
Medium (Gibco, Grand Island, NY) supplemented with 10% calf serum and 
50ug/mL gentamicin.  Cells were incubated at 37 C with 5% CO2.   
 
Drug Treatment 
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), PF15, PF158 
(Advanced Cancer Therapeutics, Louisville, KY). Chloroquine, 3-methyladenine, 
Spautin-1, Bafilomycin A1 from (Sigma, St. Louis, MO).  Samples in which 
bafilomycin A1 was used were treated with 1nM bafilomycin A1 24 hours prior to 
harvest. 
 
Protein Extraction and Immunoblotting 




Acridine Orange Immunofluorescence 
Acridine orange staining and immunofluorescence measurements were 
performed as described in Chapter II.  
 
Flow Cytometry for Cell Death 
Cell death was assessed using method described in Chapter II. 
 
 
Tumor model system 
12 week old female C57/BL6 mice were injected subcutaneously with 
1x106 Lewis lung carcinoma (LLC) cells and once tumors reached 150-200 mg, 
mice were randomized into four groups (N=6 per group): Group 1: Vehicle 
(DMSO+PBS), Group 2: Chloroquine (DMSO+50mg/kg CQ), Group 3: 3PO 
(0.07mg/g 3PO+PBS), Group 4: (0.07mg/g 3PO+50mg/kg CQ).  Drug treatments 
were based on published tumor models [53, 167, 182].  Mice were given two 
daily intraperitoneal injections with either vehicle or drug and tumors were 
measured using calipers for estimation of tumor volume.  At the conclusion of the 
study, mice were euthanized and tumors were removed.  Tumors tissues were 
fixed in paraformaldehyde and prepared for immunohistochemistry. 









Tumors excised after completion of all tumor measurements were fixed in 
paraformaldehyde for 24 hours and then embedded in paraffin, sections and 







Pharmacologic inhibition of autophagy in combination with 3PO increases 
tumor cell death  
 To determine if autophagy following 3PO treatment serves as a survival 
mechanism, chloroquine, an agent that accumulates in lysosomes and interferes 
with autophagy was used in combination with 3PO.  Treatment of HCT-116 cells 
with 15 or 30 M chloroquine led to a dose-dependent increase in cell death 
when combined with 3PO treatment as measured by flow cytometric analysis of 
annexin V and propidium iodide staining (Figure 24).   
Two additional inhibitors of autophagy were also used in combination with 
3PO to look for increased cell death, 3-methyladenine and Spautin-1.  3-
methyladenine (3MA), an inhibitor of type III phosphatidylinositol 3-kinases, 
which blocks the formation of autophagosomes was used to treat HCT-116 cells 
(1mM) that were also treated with either vehicle, or 3PO.  Cell death was 
assessed using annexin V and PI staining and quantified by flow cytometry.  The 
number of cells staining positive for both annexin V and PI was increased in 
samples treated with the combination of 3MA and 3PO relative to either drug 
alone (Figure 25).  Spautin-1, which inhibits autophagy by promoting increased 
proteasomal degradation of class III PI3 kinase complexes through inhibition of 
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ubiquitin-specific peptidases USP10 and USP13 also resulted in greater numbers 
of annexin-V and PI double positive cells when used in combination with 3PO 
(Figure 26). 
To assess whether the combined effects of autophagy inhibitors and the 
PFKFB3 inhibitor was limited only to the specific inhibitor 3PO, two other 
derivatives of 3PO were used to treat cells in combination with the autophagy 
inhibitor chloroquine.  Cell death, assessed using flow cytometry measuring 
annexin V and PI staining, was increased when chloroquine was combined with 
3PO derivative PF-158 (Figure 27) or derivative PF-15 (Figure 28). 
This increase in cell death upon the addition of chloroquine was also 
noted in HCT-116 cells that had been transfected with a siRNA directed against 











Figure 24: Synergistic increase in cell death when 3PO is combined with 
the autophagy inhibitor chloroquine.  Annexin-V/PI staining was performed in 
cells treated with vehicle, 3PO, chloroquine, or the combination of 3PO and 
chloroquine for 48 hours.  Quantitation of cell staining was performed using flow 
cytometry (Figure 24A) and the number of cells staining with both annexin-V and 
PI was quantitated and is expressed as the percentage relative to control + SD 















Figure 25: The autophagy inhibitor, 3-methyladenine, increased cell death 
when combined with 3PO.  HCT-116 cells were treated with either vehicle or 
7.5 M or 10 M 3PO + 1mM 3-methyladenine (3MA).  24 and 48 hours after 
treatment cells were stained with annexin-V and PI and measured using flow 
cytometry (Figure 25A).  Cell death was quantitated as the percentage of cells 
staining positive for annexin-V and PI relative to control + SD from three 















Figure 26.  The combination of Spautin-1 and 3PO increased cell death.  
HCT-116 cells were treated with either vehicle, 7.5 or 10 M 3PO + 15 M 
Spautin-1.  After 24 or 48 hours of treatment cells were stained with annexin-V 
and PI and collected by flow cytometry (Figure 26A).  The percentage of cells 
stained positive for both annexin-V and PI was quantitated and is expressed 














Figure 27. The 3PO derivative PF158 causes increased cell death when 
combined with chloroquine.  HCT-116 cells treated with vehicle or 0.5 M 
PF158 + 30 M CQ were stained with annexin-V and PI and collected by flow 
cytometry (Figure 27A).  Annexin-V/PI positive cells were quantitated as 
percentage of total relative to control + SD from three experiments (Figure 27B). 



























Figure 28. Cell death by PF-15, a derivative of 3PO, is increased when 
combined with chloroquine.  After treatment with either vehicle or 1M PF-15 + 
30 M chloroquine, HCT-116 cells were stained with annexin-V and PI and 
collected by flow cytometry (Figure 28A) (Figure 28A).  Cells staining positive for 
annexin-V and PI were quantitated as percentage of total relative to control 




















Figure 29: Cell death due to knockdown of PFKFB3 is increased when 
combined with the autophagy inhibitor chloroquine.  HCT-116 cells were 
transfected with either a negative control siRNA or with a PFKFB3-specific siRNA 
+ 30 M CQ.  After 48 hours of transfection, cells were stained with annexin-V 
and PI and measured using flow cytometry (Figure 29A).  Quantitation of cells 
staining positive for annexin-V and PI was performed relative to control and is 










Validation of a mouse tumor cell line prior to in vivo experiment 
 Before moving to an in vivo model, a mouse tumor cell line, Lewis lung 
carcinoma (LLC) was evaluated for autophagy and increased sensitivity to 
chloroquine following treatment with 3PO.   Lewis lung carcinoma cells treated 
with 10 M 3PO had increased levels of LC3-II relative to control.  This increase 
was further enhanced upon the addition of bafilomycin A1 (Figure 30).  Acridine 
orange immunofluorescence was also increased by 10M 3PO in LLC cells as 
determined visually by fluorescence microscopy (Figure 31 A), and quantified by 
flow cytometry (Figure 31B).  Similar to the HCT-116 cells, Lewis lung carcinoma 
cell death was also increased when chloroquine treatment was used in 












Figure 30: Autophagic protein marker LC3-II is increased in Lewis lung 
carcinoma cells exposed to 3PO.  LLC cells were treated with 25 M 3PO for 
24 hours.  LC3-II levels were measured using immunoblotting and quantitative 
densitometry was performed.  Levels expressed as mean fold change LC3-II/β 





















Figure 31: Lewis lung carcinoma cells treated with 3PO have increased 
acridine orange staining. LLC cells treated with 25 M 3PO for 24 hours were 
stained with acridine orange.  Cells were viewed by fluorescent microscopy and 
representative images were taken (Figure 31A).  Flow cytometry was performed 
and the relative number of cells with a high level of acridine orange staining was 
quantitated and is expressed as the mean + SD from three experiments (Figure 
















Figure 32: The combination of 3PO and chloroquine has synergistic effects 
on cell death in Lewis lung carcinoma cells.  LLC cells were treated with 
either vehicle or 10 M 3PO + either 15 or 30 M CQ.  After 24 hours of 
treatment cells were stained with annexin-V and PI and measured using flow 
cytometry (Figure 32A).  Cells staining positive for both annexin-V and PI were 
quantitated as the percentage of the total relative to control and data is presented 
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Combination of autophagy inhibition and 3PO decreases tumor growth in 
vivo 
 12 week old female C57/BL6 mice were used to determine the in vivo 
effect of the combination of chloroquine and 3PO on tumor growth.  Animals 
were injected subcutaneously with 1x106 Lewis lung carcinoma cells.  When 
tumors reached 150-200 mm3, calculated based on volume, mice were 
randomized into four treatment groups (N=6 per group).  Group 1: Vehicle 
(DMSO+PBS), Group 2: Chloroquine (DMSO+50mg/kg CQ), Group 3: 3PO 
(0.07mg/g 3PO+PBS), Group 4: (0.07mg/g 3PO+50mg/kg CQ).   Daily tumor 
measurements were obtained using calipers for estimation of tumor mass.  The 
experiment was concluded two weeks from the start of drug treatment and 
tumors were collected for further examination.  The tumor mass was significantly 
reduced in animals treated with both 3PO and chloroquine relative to either drug 
treatment alone (Figure 33).  Excised tumors were fixed and prepared for 
immunohistochemistry.  The tumor sections were stained with an antibody 
recognizing cleaved caspase-3, a key protein in the execution phase of 
apoptosis.  Tumors from animals treated with the combination of 3PO and 
chloroquine were noted to have an increased number of cleaved caspase-3 









Figure 33: Combination therapy using 3PO and chloroquine reduces tumor 
growth in a Lewis lung carcinoma tumor model in vivo.  C57/BL6 mice were 
inoculated with 1x106 Lewis lung carcinoma cells by subcutaneous flank 
injection.  Mice were randomized into 4 treatment groups when tumors reached 
150-200 mm3 and were treated by i.p. injections with either vehicle, 50mg/kg 
chloroquine, 0.07mg/g 3PO, or a combination of the two drugs.  Tumor 
measurements taken over the course of treatment were used to calculate tumor 


























Figure 34: Immunohistochemistry of excised tumors from 3PO + 
chloroquine treated animals have increased cleaved-caspase 3 staining.  
Tumors were fixed, paraffin embedded and stained with an antibody directed 
against cleaved caspase-3 (CC3).  The number of cells staining positive for CC3 
was in a 200X field was counted and data is expressed as the mean + SD from 











The increasing identification of autophagy as a resistance mechanism 
utilized by tumor cells to avoid destruction led to postulation of improved anti-
tumor effects by the combination of autophagy inhibitors with PFKFB3 inhibitors.  
We have shown that cell death following treatment with PFKFB3 inhibitor 3PO 
was increased when combined with autophagy inhibitors chloroquine, 3-
methyladeneine or Spautin-1.  Additionally, chloroquine increased cell death 
when combined with other derivatives of the PFKFB3 inhibitor 3PO, PF-158 and 
PF-15, showing that the combination of chloroquine is not limited to only one 
PFKFB3 inhibitor.  While these inhibitors, 3PO, PF-158 and PF-15, have been 
shown to inhibit PFKFB3 enzyme activity, these compounds most certainly have 
some off-target effects.  For this reason, chloroquine was also tested in 
combination with PFKFB3 siRNA and enhanced cell death was noted.  These 
observations support the role of autophagy as a resistance mechanism following 
the inhibition of PFKFB3 activity. 
While in vitro research is absolutely essential to the understanding of cell 
function, data collected is limited by unforeseen effects that occur only in vivo.  
Animal studies are laborious, costly, and, even more importantly, result in the 
expenditure of numerous animal lives.  Once sufficient data has been compiled 
from in vitro work, it is necessary and responsible to expand studies to an animal 
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model system in order to increase its relevance.  This is especially important 
when evaluating drugs or combinations of drugs due to unanticipated systemic 
effects that can occur.   
Chloroquine has been safely used as an anti-malarial agent since the 
1940’s and has more recently been used as an anti-tumor agent.  Based on 
previously reported animal tumor studies using chloroquine, a dose of 50mg/kg 
was selected [36, 54, 183, 184].  The dose of 3PO used for this study (0.07mg/g) 
was also selected based on a previously published animal tumor model [53].  
The combination of 3PO and chloroquine resulted in significantly smaller tumors 
relative to either drug treatment alone.  While there was a substantial difference 
in tumor size, it is important to note that 3PO treatment alone did not have the 
same anti-tumor effects that were seen in the previously published work [53], 
although the tumor model (Lewis lung carcinoma tumors in C57/BL6 mice) was 
the same.  Additionally, although the model system was different, tumors from 
animals treated with chloroquine alone failed to show any difference in tumor 
size, contrasting with other published tumor studies [183, 184].  While this may 
be due to the use of slower growing tumor models that are not as sensitive to 
chloroquine the LLC tumors grew very quickly, with the first tumors palpable 
merely three days after inoculation.  Drug treatment was started when tumors 
reached between 150-200 mm3, calculated based on caliper measurements, 
which was less than one week after inoculation for most animals, in contrast to 
two to four weeks between inoculation and drug treatment in other models [183, 
184].  In fact, in those studies it was not until more than three weeks after tumor 
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inoculation that the average tumor mass in chloroquine-treated animals was 
smaller than the vehicle treated, which is longer than the length of the entire 
study presented here [184].  In this setting it is reasonable to speculate that the 
drugs may have had a difficult time competing with the accelerated growth of 
tumors. Future studies may benefit from using a slower growing model system so 
that treatment time can be extended.  
Tumors that were removed from animals at the conclusion of the study 
were fixed and stained with a marker of cell death, cleaved-caspase 3.  This 
marker was increased in tumors excised from animals treated with the 
combination of chloroquine and 3PO relative to those from animals treated with 
either drug alone.  The smaller tumor size and increased CC3 staining supports 
the idea that autophagy is serving as a protective mechanism following PFKFB3 
inhibition and that the efficacy of PFKFB3 inhibitors as anti-cancer agents may 










Figure 35. Inhibition of glycolysis causes induction of autophagy for 
survival.  Metabolic stress due to PFKFB3 knockdown results in AMPK 
activation and subsequent mTOR inhibition which relieves autophagy 
suppression allowing for increased cell survival.  PFKFB3 inhibition using 3PO 
results in a much more rapid inhibition of glycolysis resulting in acute oxidative 
changes that lead to mTOR inhibition and autophagy induction.  Adding 


















Harnessing our knowledge gained from studying cancer cells over the 
past century in order to determine the traits that distinguish them from normal 
cells is paramount to developing cancer-specific therapies.  Inhibition of 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) has proven to 
effectively and specifically target tumor cells in vitro and to decrease tumor 
burden in vivo [53].  Clinical trials using PFKFB3 inhibitors are forthcoming.  
However, like so many chemotherapeutics, it is not unexpected that resistance to 
these inhibitors could be encountered in the setting of human cancers.  
Resistance is often battled using combinations of drugs, which have now become 
standard, making single drug therapies quite rare.  Elucidating the specific 
resistance mechanisms triggered by chemotherapeutic drugs allows for the 
selection of combinations that might work to combat such resistance with the 
hope of increasing efficacy.  In this work we show that autophagy is induced by 
PFKFB3 inhibition and that this induction is likely serving as a resistance 
mechanism as supported by the observations of increased cell death in vitro and
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slowed tumor growth in vivo when combined with pharmacologic inhibitors of 
autophagy.  It is likely that the use of drugs targeting PFKFB3 in human cancers 
will benefit from combinatorial therapies, such as that supported here with the 







EXPANSION OF MODELING SYSTEMS 
Like Galileo’s heliocentric model of the universe, Warburg’s theory 
regarding tumor cell metabolism, while still a major contribution to our 
understanding of tumor cell metabolism, may be flawed.  He originally proposed 
that cancer cells utilized glycolysis due to damaged mitochondria preventing 
efficient oxidative respiration [2].  It is now thought that mitochondrial defects are 
somewhat rare and that most tumor cells not only have the capacity for but also 
utilize oxidative metabolism, albeit at reduced rates [185].  Still, it is clear that the 
increased uptake and utilization of glucose is a distinguishing attribute of tumor 
cells relative to normal cells, a feature that is taken advantage of for visualizing 
tumors by PET scanning using 2-deoxy-2-(18F)fluoro-D-glucose positron 
emission tomography (FDG-PET) imaging.   
To account for the increased uptake in glucose of tumors despite 
functional mitochondrial an alternative hypothesis, termed the “Reverse Warburg 
Effect” was proposed [186].  It postulates that the increased glycolytic flux in 
tumors is not due to the cancer cells themselves, but to stromal cells in the tumor 
microenvironment.  In this model, oxidative stress resulting from cancer cell 
release of H2O2 stimulates stromal cells to undergo autophagy, and, in particular, 
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selective mitochondrial autophagy, leaving them dependent on glycolysis for 
energy production [187, 188].  Thus, it is the stromal cancer-associated 
fibroblasts that are responsible for increased glucose uptake and utilization.  
These fibroblasts are then observed to release lactate and pyruvate as a result of 
increased glycolytic flux, which is taken up as a fuel for mitochondrial respiration 
in the cancer cells.   In support of this theory, cancer cells co-cultured with 
fibroblasts were observed to have increased mitochondrial mass and decreased 
glycolytic flux relative to cancer cells cultured alone.   Additionally, fibroblasts co-
cultured with cancer cells had decreased mitochondrial activity [189].   Whether it 
is due to stromal cells or to cancer cells or both, it is clear that tumors take up 
more glucose than normal tissues.  It is reasonable to speculate that anti-
glycolytic drugs, such as PFKFB3 inhibitors, will be more effective as cytostatic 
or cytotoxic agents in cells with increased glycolytic potential.  For this reason it 
would be important to return to the in vitro system and look at PFKFB3 inhibition 
in the setting of co-cultures of tumor cells and fibroblasts to determine if one cell 
type seems to be affected more than the other.  In this same model system, other 
consequences of PFKFB3 inhibition, such as the induction of autophagy, could 
be measured to understand how cells within the tumor environment behave in.   
Additionally, the work presented in this dissertation is limited by the model 
system used to evaluate PFKFB3 knockdown or inhibition.  Future studies will 
also be conducted in multiple cell lines including a variety of tumor cells 
originating from different organs as well as in normal cells derived from primary 




with more specific autophagy inhibitors.  The use of chloroquine in this work was 
based on its action to inhibit autophagy and its long-standing safety profile in 
humans.  As the autophagy field expands, it is likely that more inhibitors will be 
developed that have greater specificity for the autophagic process.  This could 
mean that these agents are more tumor-specific and will have greater anti-tumor 
effects than chloroquine. As well as expanding the variety of drugs used to inhibit 
autophagy, it will be important to test newer derivatives of PFKFB3 inhibitors with 
fewer off-target effects and with lower toxicity ranges. 
Another limitation of the work presented here is the singular in vivo model 
system.  The animal study was performed using a mouse tumor cell line.  More 
sophisticated, and also more expensive, xenograft modeling systems that utilize 
human cancer cells in an immunodeficient athymic mouse may more 
appropriately simulate the effect that PFKFB3 inhibitors will have on human 
cancers. 
 
UNDERSTANDING THE ROLE FOR GLUTAMINOLYSIS  
Other studies that could further our understanding of the role of PFKFB3 
in cancer and the consequences of inhibition as a means to treat cancer should 
be focused on glutamine metabolism.  Glutamine is another substrate, in addition 
to glucose, that is utilized to a greater extent in cancer cells relative to normal 
cells [190, 191].  Glucose deprivation is known to induce glutaminolysis which 
increases the synthesis of TCA intermediates, reduces oxidative stress by 
production of NADPH, and also causes increased ammonia, a known inducer of 
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autophagy [192-194].  Glutamine can also be used to make GSH.  Glutaminase 
converts glutamine to glutamate which can be acted upon by glutathione cysteine 
ligase to be converted directly to GSH [195]. A gradual reduction in PFKFB3 
using siRNA may result in the transition to utilization of glutamine as an 
alternative energy source.  The subsequent metabolism of glutamine could be 
used to increase GSH, thus limiting reactive oxygen species.  In fact, in data not 
shown, PFKFB3 knockdown was observed to result in less reactive oxygen 
species and in stabilization of the intracellular GSH pool.  Conversely, the rapid 
decline in glucose uptake resulting from PFKFB3 inhibition using 3PO may lead 
to excessive reactive oxygen species that causes utilization and a decrease in 
the GSH pool, occurring before the cell has the time to utilize glutamine and 
counteract oxidative stress with increased GSH synthesis.   Clearly it would be of 
great interest to study glutaminolysis in the setting of both PFKFB3 knockdown 
and PFKFB3 inhibition.  As part of this endeavor, 14C-labeled glutamine might be 
used to measure glutamine uptake via scintillation counts in cells that treated 
with either PFKFB3 siRNA or with pharmacologic PFKFB3 inhibitors.  
Additionally, 13C-labeled glutamine could be used by nuclear magnetic resonance 
studies to understand how glutamine metabolism is altered in cells in which 
PFKFB3 is manipulated.  Depending on the results of these studies, 
glutaminolytic modulators may be combined with PFKFB3 inhibitors to look for 






EXPLOITING OXIDATIVE STRESS 
Another combination approach that may result in more effective cancer 
therapies is that of PFKFB3 inhibitors and drugs known to cause oxidative stress.  
The induction of ROS by PFKFB3 inhibition, and the additive effects on tumor 
cell death upon combination with chloroquine, a compound that, itself, has been 
shown to increase ROS, may mean that the combinatorial effects on cell death 
are due to a massive increase in ROS that tumor cells cannot battle [196].  There 
are a number of examples where utilization of drugs known to increase reactive 
oxygen species and oxidative stress have been successfully combined with 
chemotherapeutic drugs, a topic that has previously been reviewed [197].  Thus, 
it is possible that the combination of PFKFB3 inhibitors with these pro-oxidative 
agents will have even greater success than the combination with chloroquine.  In 
fact, glucose-withdrawal induced oxidative stress has been observed to be 
greater in some tumor cells relative to normal cells which could indicate 
increased tumor specificity of this type of combination with PFKFB3 inhibitors 
[198] 
In order to gain a greater understanding of how PFKFB3 manipulation 
affects oxidative stress, the source of stress must be elucidated.  As previously 
stated, changes in glutamine metabolism may have a role in the production of 
GSH and, thus, the mitigation of damage that could be caused by ROS.  
Additionally, it will be important to measure the changes in mitochondrial mass, 
and function, by measuring membrane potential, oxygen consumption, and the 
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production of mitochondrial-specific reactive oxygen species, after PFKFB3 
manipulation. 
 
THE HUMAN PERSPECTIVE 
In vitro culture systems and in vivo animal modeling can only take us so 
far in the search for a cure to cancer.  To treat human cancers we need to better 
understand their characteristics and functional requirements in their natural 
environment.  Observing that some measure of metabolism or that expression of 
an activated protein in a pathway presumed to be important in cancer cells is 
changed after 6, 12, or 24 hours of treatment is not as meaningful as looking at 
what is happening in the majority of tumor cells at any point in time within the 
human body.  Perhaps even more importantly, determining how tumors, as a 
whole, react to treatment with chemotherapeutics is critical to how we will move 
forward to treat tumors and to modify treatments based on a tumor’s response to 
treatment.  As part of this mission, it would be of great interest to examine 
samples taken from a variety of human tumors and measure PFKFB3 expression 
and markers of autophagy to look for correlations between glycolytic and 
autophagic activity.  Additionally, once PFKFB3 inhibitors enter human cancer 
trials, tumor samples could be examined after treatment for assessment of 
autophagy markers.  Correlations between the response of particular tumors, 
growth, shrinkage, or stabilization of tumor size with these autophagic markers 
could be used to make therapeutic modifications, for example, the addition of 




 Work presented herein supports the protective role of autophagy in cancer 
cells following inhibition of PFKFB3, a key enzyme involved in the regulation of 
glycolysis.  Treatment using PFKFB3 inhibitors and autophagy inhibitors, such as 
chloroquine, have shown promise as a combinatorial approach to tumor therapy.  
Still, as detailed above, a considerable amount of work needs to be 
accomplished to gain a better grasp on how to effectively target tumors by 
inhibiting PFKFB3.  Hopefully the studies presented in this dissertation will serve 
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